Last updated on January 2019

Treat-to-target With Secukinumab in Axial Spondyloarthritis


Brief description of study

A study of axSpA and AS receiving Secukinumab in a treat-to-target strategy.

Detailed Study Description

Comparison of reductions in MRI inflammation in the sacroiliac joints and spine from week 16 to 24 in patients who at week 16 are in ASDAS remission (i.e. continue sc. secukinumab 150 mg monthly) vs. not in ASDAS remission (i.e. increase sc. secukinumab 300 mg monthly). ASDAS remission is defined as ASDAS inactive disease i.e. ASDAS<1.3.

Clinical Study Identifier: NCT03639740

Contact Investigators or Research Sites near you

Start Over

Bente Jensen, MD PhD

Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet - Frederiksberg
Frederiksberg, Denmark
  Connect »

Mikkel Østergaard, MD PhD DMSc

Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet Glostrup
Glostrup, Denmark
3.95miles
  Connect »

Ole R Madsen, MD PhD ...

Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet - Gentofte
Hellerup, Denmark
4.46miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.